Skip to content

Comparative Observation of the Anesthetic Effects of Sufentanil Combined with Ciprofol and Remazolam on Painless Gastroscopy at Different Entry Points

Comparative Observation of the Anesthetic Effects of Sufentanil Combined with Ciprofol and Remazolam on Painless Gastroscopy at Different Entry Points

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075880
Enrollment
Unknown
Registered
2023-09-19
Start date
2023-09-19
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroenteritis and polyps

Interventions

Sponsors

Harbin Medical University Affiliated Fourth Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Participants in the study of gastroscopy of the digestive tract under intravenous anesthesia; 2) Research participants voluntarily participate and sign informed consent forms; 3) Age 18-70 years old; 4) The American Society of Anesthesiologists (ASA) anesthesia classification is grades I to II; 5) Malampati airway grading I to II; 6) 18 = BMI = 28kg/?

Exclusion criteria

Exclusion criteria: 1) Research participants are unwilling to sign informed consent forms; 2) Allergies to benzodiazepines and any components of this product; 3) Myasthenia gravis; 4) Schizophrenia and severe depressive state; 5) Pathological obesity/obstructive sleep apnea; 6) Acute upper respiratory tract infection; 7) Asthma attack period; 8) Uncontrolled severe hypertension; 9) Unstable angina pectoris; 10) Severe liver dysfunction; 11) Acute upper gastrointestinal bleeding with shock; 12) Severe anemia; 13) Gastrointestinal obstruction with retention of gastric contents; 14) Long term history of taking sedative and analgesic drugs and individuals with allergies

Design outcomes

Secondary

MeasureTime frame
Changes in vital signs;Use of vasoactive drugs;Total Remazolam;

Primary

MeasureTime frame
adverse event;

Countries

China

Contacts

Public ContactGao Xiaoying

Harbin Medical University Affiliated Fourth Hospital

13936259853@163.com+86 139 3625 9853

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026